AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
This piece identifies funds with the highest management charges in the Dividend Aristocrats group and explains potential impact on performance.
26,423 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A notable fund liquidated its entire Ascendis Pharma stake, signaling a strategic rotation in a volatile biotech sect...
When a fund sold $5.5 million of a regional bank, headlines lit up. But one big trade rarely tells the whole story. T...
Longbridge's Q1 results set a quarterly high and eclipsed its 2025 full-year profit, highlighting strong reverse-mort...
As inflation remains persistent, traders are moving away from speculative growth toward dependable income. Carvana is...
A $1.4 million portfolio that generates roughly $49,000 in annual income could outpace the average California public ...
With the Fed set to act this month, a dirt-cheap stock looks attractive amid crosscurrents in the market. Here’s why ...
As markets stabilize in 2026, a new approach to retirement planning promotes spending more now with a structured, ris...
Emails released in SEC filings reveal a heated confrontation between UWM and Two Harbors as the CCM deal vote approac...
A recent talent exodus rattled Alphabet, but the long-term AI moat, cloud momentum, and strong cash flow argue for pa...
International small caps have surged about 35% over the past year as value and profitability themes take hold in deve...
Microsoft's stock has faced a meaningful pullback this year. This article unpacks the factors behind the drop, evalua...